Sars-cov-2 vaccines
US-2024408193-A1 · Dec 12, 2024 · US
Optimized HIV envelope gene and expression thereof
US10792357B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10792357-B2 |
| Application number | US-201916291073-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 4, 2019 |
| Priority date | Oct 27, 2014 |
| Publication date | Oct 6, 2020 |
| Grant date | Oct 6, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a vector(s) containing and expressing an optimized HIV EnvF gene, methods for making the same and cell substrates qualified for vaccine production which may comprise vector(s) containing optimized HIV genes.
First claim
Opening claim text (preview).
What is claimed is: 1. A viral vector containing and expressing a nucleic acid encoding a Clade A Env-F hybrid based on BG505, wherein the Env signal sequence (SS), transmembrane region (TMR), and the cytoplasmic tail (CT) of HIV-Env-F are replaced with an analogous sequence from the Sendai virus F gene. 2. The vector of claim 1 , wherein the nucleic acid comprises the nucleic acid sequence of SEQ ID NO: 18. 3. The vector of claim 1 , wherein the nucleic acid encodes an amino acid sequence of the HIV immunogen comprises the amino acid sequence of SEQ ID NO: 19. 4. The vector of claim 1 , wherein the vector is a canine distemper virus (CDV) or a vesicular stomatitis virus (VSV) vector. 5. A cell transfected with the vector of claim 1 . 6. The cell of claim 5 wherein the cell is a Vero cell. 7. A method for eliciting an immune response against HIV comprising administering an effective amount of the vector of claim 1 to a mammal in need thereof. 8. The method of claim 7 further comprising administering an adjuvant. 9. The method of claim 8 , wherein the adjuvant is comprised of an acrylic polymer.
Assignees
Inventors
Classifications
- A61K39/12Primary
Viral antigens · CPC title
Paramyxoviridae, e.g. parainfluenza virus · CPC title
for HIV · CPC title
viral genome or elements thereof as genetic vector · CPC title
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10792357B2 cover?
- The present invention relates to a vector(s) containing and expressing an optimized HIV EnvF gene, methods for making the same and cell substrates qualified for vaccine production which may comprise vector(s) containing optimized HIV genes.
- Who is the assignee on this patent?
- Int Aids Vaccine Initiative
- What technology area does this patent fall under?
- Primary CPC classification A61K39/12. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 06 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).